AGR2 ELISA kit (Human)

SKU: SEC285Hu

Size: 96Tests

# of Times Cited in literature: 12

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: AGR2

Target Full Name: Anterior Gradient 2

Alternative Names: GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog

Target Species: Human

Uniprot: O95994

Gene ID: 10551

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human AGR2 / Anterior Gradient 2

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 1.56-100ng/mL

Sensitivity: 0.55ng/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Tissue Homogenates, Cell Lysates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anterior Gradient 2 (AGR2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anterior Gradient 2 (AGR2) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Anterior Gradient 2 (AGR2). No significant cross-reactivity or interference between Anterior Gradient 2 (AGR2) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Anterior Gradient 2 (AGR2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Anterior Gradient 2 (AGR2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Anterior Gradient 2 (AGR2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Anterior Gradient 2 (AGR2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Tumor immunity;Reproductive science;Bone metabolism;

References Citing This Product: Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma

Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer

AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection

Serum AGR2 as a useful biomarker for pituitary adenomas

Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)

Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy‑induced senescence escape

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer